Pieris Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s stock is scheduled to reverse split before the market opens on Tuesday, April 23rd. The 1-80 reverse split was announced on Tuesday, April 23rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, April 23rd.

Pieris Pharmaceuticals Price Performance

Shares of PIRS opened at $0.15 on Friday. The firm’s 50 day moving average is $0.17 and its 200-day moving average is $0.20. The stock has a market capitalization of $14.34 million, a P/E ratio of -0.52 and a beta of 0.48. Pieris Pharmaceuticals has a 12-month low of $0.14 and a 12-month high of $1.01.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $1.30 million during the quarter. Pieris Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 57.33%.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Pieris Pharmaceuticals in a research note on Saturday, April 13th. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On Pieris Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its position in shares of Pieris Pharmaceuticals by 9,665.2% in the third quarter. Tower Research Capital LLC TRC now owns 21,581 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 21,360 shares in the last quarter. Raymond James & Associates increased its position in shares of Pieris Pharmaceuticals by 50.0% in the fourth quarter. Raymond James & Associates now owns 30,000 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 10,000 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Pieris Pharmaceuticals in the first quarter worth approximately $32,000. Mirabella Financial Services LLP purchased a new position in shares of Pieris Pharmaceuticals in the first quarter worth approximately $39,000. Finally, Two Sigma Investments LP purchased a new position in shares of Pieris Pharmaceuticals in the third quarter worth approximately $43,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.